These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38551080)

  • 1. Perceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment.
    Gaeta Gazzola M; Oberleitner LMS; Hoffman K; Eller A; Madden LM; Marcus R; Oberleitner D; Beitel M; Thompson E; Zheng X; Barry DT
    Subst Use Addctn J; 2024 Oct; 45(4):568-576. PubMed ID: 38551080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
    Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
    Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV; Whitcomb M; Buchheit BM; Dorr DA; Malinoski DJ; Korthuis PT; Ono SS; Levander XA
    Harm Reduct J; 2024 Jun; 21(1):125. PubMed ID: 38937779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
    Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
    J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
    Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B
    Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of familial networks and stigma on prison-based medication initiation for individuals with opioid use disorder: Clinicians' perceptions.
    Rockett ML; Knudsen HK; Oser CB
    J Subst Use Addict Treat; 2024 Jul; 162():209353. PubMed ID: 38521351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study.
    Pinhal M; Schreck B; Leboucher J; ; Victorri-Vigneau C; Laforgue EJ; Grall-Bronnec M
    Addict Sci Clin Pract; 2024 Oct; 19(1):74. PubMed ID: 39415293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.
    Rich JD; McKenzie M; Larney S; Wong JB; Tran L; Clarke J; Noska A; Reddy M; Zaller N
    Lancet; 2015 Jul; 386(9991):350-9. PubMed ID: 26028120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach.
    Bunting AM; Oser CB; Staton M; Eddens KS; Knudsen H
    Addict Sci Clin Pract; 2018 Dec; 13(1):23. PubMed ID: 30509314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments.
    Maradiaga JA; Nahvi S; Cunningham CO; Sanchez J; Fox AD
    J Subst Abuse Treat; 2016 Mar; 62():49-54. PubMed ID: 26747509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technical violations and infractions are drivers of disengagement from methadone treatment among people with opioid use disorder discharged from Connecticut jails 2014-2018.
    Marotta P; Hass A; Viera A; Doernberg M; Barbour R; Grau LE; Heimer R
    Subst Abuse Treat Prev Policy; 2023 Jul; 18(1):43. PubMed ID: 37420271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
    Vail W; Faro E; Watnick D; Giftos J; Fox AD
    Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
    Benville JR; Compton P; Giordano NA; Cheatle MD
    Drug Alcohol Depend; 2021 Apr; 221():108619. PubMed ID: 33667781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).
    Smith LR; Mittal ML; Wagner K; Copenhaver MM; Cunningham CO; Earnshaw VA
    Addiction; 2020 Feb; 115(2):354-367. PubMed ID: 31478272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.